ZA200701232B
(en)
|
2004-07-15 |
2008-08-27 |
Amr Technology Inc |
Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
|
NZ594628A
(en)
*
|
2005-10-07 |
2013-04-26 |
Exelixis Inc |
PYRIDOPYRIMIDINONE INHIBITORS OF PI3Ka
|
MY162590A
(en)
|
2005-12-13 |
2017-06-30 |
Incyte Holdings Corp |
Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors
|
TW200817410A
(en)
|
2006-08-07 |
2008-04-16 |
Incyte Corp |
Triazolotriazines as kinase inhibitors
|
CN101594909A
(zh)
*
|
2006-09-07 |
2009-12-02 |
比奥根艾迪克Ma公司 |
用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂
|
JP2010506948A
(ja)
*
|
2006-10-20 |
2010-03-04 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
C−kitおよびpdgfr受容体を調節するための組成物および方法
|
JP5572388B2
(ja)
|
2006-11-22 |
2014-08-13 |
インサイト・コーポレイション |
キナーゼ阻害剤としてのイミダゾトリアジンおよびイミダゾピリミジン
|
AR067326A1
(es)
*
|
2007-05-11 |
2009-10-07 |
Novartis Ag |
Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido
|
EP3495369B1
(en)
|
2007-06-13 |
2021-10-27 |
Incyte Holdings Corporation |
Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
|
FR2918061B1
(fr)
*
|
2007-06-28 |
2010-10-22 |
Sanofi Aventis |
Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique.
|
JP5774982B2
(ja)
*
|
2008-05-19 |
2015-09-09 |
サノビオン ファーマシューティカルズ インクSunovion Pharmaceuticals Inc. |
イミダゾ[1,2−a]ピリジン化合物
|
MX2010012718A
(es)
|
2008-05-21 |
2011-04-04 |
Incyte Corp |
Sales de 2-fluoro-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b ][1,2,4] triazin-2-il]benzamida y procesos relacionados con la preparacion de las mismas.
|
US9156812B2
(en)
|
2008-06-04 |
2015-10-13 |
Bristol-Myers Squibb Company |
Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
|
AR071997A1
(es)
*
|
2008-06-04 |
2010-07-28 |
Bristol Myers Squibb Co |
Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
|
US8987251B2
(en)
|
2008-08-19 |
2015-03-24 |
Array Biopharma Inc. |
Triazolopyridine compounds as PIM kinase inhibitors
|
TWI496779B
(zh)
*
|
2008-08-19 |
2015-08-21 |
Array Biopharma Inc |
作為pim激酶抑制劑之***吡啶化合物
|
US8895550B2
(en)
|
2008-08-19 |
2014-11-25 |
Array Biopharma Inc. |
Triazolopyridine compounds as PIM kinase inhibitors
|
WO2010022081A1
(en)
*
|
2008-08-19 |
2010-02-25 |
Array Biopharma Inc. |
Triazolopyridine compounds as pim kinase inhibitors
|
PT2350075E
(pt)
|
2008-09-22 |
2014-06-09 |
Array Biopharma Inc |
Compostos imidazo[1,2b]piridazina substituídos como inibidores da trk cinase
|
CL2009001884A1
(es)
*
|
2008-10-02 |
2010-05-14 |
Incyte Holdings Corp |
Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
|
SG10201914059WA
(en)
|
2008-10-22 |
2020-03-30 |
Array Biopharma Inc |
Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
|
KR20120034644A
(ko)
|
2009-05-12 |
2012-04-12 |
알바니 몰레큘라 리써치, 인크. |
아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도
|
JP2012527479A
(ja)
*
|
2009-05-20 |
2012-11-08 |
サイリーン ファーマシューティカルズ インコーポレーティッド |
キナーゼ阻害剤としてのピラゾロピリミジンおよび関連の複素環化合物
|
EA025520B1
(ru)
|
2009-05-22 |
2017-01-30 |
Инсайт Холдингс Корпорейшн |
N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
|
MX2011012262A
(es)
|
2009-05-22 |
2012-01-25 |
Incyte Corp |
3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il] octano-o heptano-nitrilo como inhibidores de cinasas janus (jak).
|
AR077468A1
(es)
|
2009-07-09 |
2011-08-31 |
Array Biopharma Inc |
Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
|
TW201113285A
(en)
|
2009-09-01 |
2011-04-16 |
Incyte Corp |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
US9227971B2
(en)
|
2010-01-19 |
2016-01-05 |
Merck Sharp & Dohme Corp. |
Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors
|
ES2608329T3
(es)
|
2010-02-03 |
2017-04-07 |
Incyte Holdings Corporation |
Imidazo[1,2-b][1,2,4]triazinas como inhibidores de c-Met
|
US8901137B2
(en)
|
2010-02-09 |
2014-12-02 |
Exelixis, Inc. |
Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors
|
SI3354652T1
(sl)
*
|
2010-03-10 |
2020-08-31 |
Incyte Holdings Corporation |
Derivati piperidin-4-il azetidina kot inhibitorji JAK1
|
EP2563792B1
(en)
*
|
2010-04-28 |
2014-08-27 |
Bristol-Myers Squibb Company |
Imidazopyridazinyl compounds and their uses for cancer
|
US9156827B2
(en)
|
2010-04-30 |
2015-10-13 |
The University Of Tokyo |
Anticancer agent
|
MX365251B
(es)
|
2010-05-20 |
2019-05-28 |
Array Biopharma Inc |
Compuestos macrocíclicos como inhibidores de trk cinasa.
|
SG10201910912TA
(en)
|
2010-05-21 |
2020-01-30 |
Incyte Corp |
Topical Formulation for a JAK Inhibitor
|
BR112013012502A2
(pt)
|
2010-11-19 |
2019-03-06 |
Incyte Corporation |
pirrolopiridina ciclobutil substituída e derivados de pirrolopirimidina derivativos como inibidores de jak
|
US9034884B2
(en)
|
2010-11-19 |
2015-05-19 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
|
WO2012154274A1
(en)
|
2011-02-25 |
2012-11-15 |
Array Biopharma Inc. |
Triazolopyridine compounds as pim kinase inhibitors
|
CA2836203A1
(en)
|
2011-05-17 |
2012-11-22 |
Bayer Intellectual Property Gmbh |
Amino-substituted imidazopyridazines as mknk1 kinase inhibitors
|
CN103717604B
(zh)
|
2011-06-01 |
2016-06-01 |
拜耳知识产权有限责任公司 |
取代的氨基咪唑并哒嗪
|
MY165963A
(en)
|
2011-06-20 |
2018-05-18 |
Incyte Holdings Corp |
Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
|
US9284319B2
(en)
|
2011-06-22 |
2016-03-15 |
Bayer Intellectual Property Gmbh |
Heterocyclyl aminoimidazopyridazines
|
WO2013005041A1
(en)
*
|
2011-07-07 |
2013-01-10 |
Centro Nacional De Investigaciones Oncológicas (Cnio) |
Tricyclic heterocyclic compounds as kinase inhibitors
|
ES2671748T3
(es)
*
|
2011-07-21 |
2018-06-08 |
Tolero Pharmaceuticals, Inc. |
Inhibidores heterocíclicos de proteína quinasas
|
EP2742046A1
(en)
*
|
2011-08-12 |
2014-06-18 |
F.Hoffmann-La Roche Ag |
PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為jak抑制劑之環己基氮雜環丁烷衍生物
|
UA117092C2
(uk)
|
2011-09-06 |
2018-06-25 |
Байєр Інтеллектуал Проперті Гмбх |
Амінозаміщені імідазопіридазини
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
US9320737B2
(en)
|
2011-09-23 |
2016-04-26 |
Bayer Intellectual Property Gmbh |
Substituted imidazopyridazines
|
HUE029728T2
(en)
*
|
2011-09-30 |
2017-03-28 |
Ipsen Pharma Sas |
Macrocyclic LRRK2 kinase inhibitors
|
CA2849999A1
(en)
|
2011-09-30 |
2013-04-04 |
Oncodesign S.A. |
Macrocyclic flt3 kinase inhibitors
|
WO2013051672A1
(ja)
*
|
2011-10-04 |
2013-04-11 |
株式会社ヤクルト本社 |
チアゾリジン誘導体又はその塩を有効成分とする医薬品
|
ES2650915T3
(es)
*
|
2011-12-12 |
2018-01-23 |
Bayer Intellectual Property Gmbh |
Imidazopiridazinas amino-sustituidas
|
US9777004B2
(en)
|
2012-03-29 |
2017-10-03 |
Bayer Intellectual Property Gmbh |
Amino-substituted imidazopyridazines
|
US10280168B2
(en)
|
2012-03-30 |
2019-05-07 |
Agency For Science, Technology And Research |
Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof
|
GB201205669D0
(en)
*
|
2012-03-30 |
2012-05-16 |
Agency Science Tech & Res |
Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
|
CA2869212A1
(en)
|
2012-04-04 |
2013-10-10 |
Bayer Pharma Aktiengesellschaft |
Amino-substituted imidazopyridazines
|
US9193733B2
(en)
|
2012-05-18 |
2015-11-24 |
Incyte Holdings Corporation |
Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
|
TWI585088B
(zh)
*
|
2012-06-04 |
2017-06-01 |
第一三共股份有限公司 |
作爲激酶抑制劑之咪唑并[1,2-b]嗒衍生物
|
CN104797267A
(zh)
|
2012-06-26 |
2015-07-22 |
德玛医药 |
使用卫康醇、二乙酰二脱水卫矛醇、二溴卫矛醇或类似物或其衍生物治疗具有基因多型性或ahi1失调或突变患者的抗酪氨酸激酶抑制剂的恶性肿瘤的方法
|
SG11201503695XA
(en)
|
2012-11-15 |
2015-06-29 |
Incyte Corp |
Sustained-release dosage forms of ruxolitinib
|
CA2889919C
(en)
|
2012-11-16 |
2021-08-17 |
University Health Network |
Pyrazolopyrimidine compounds
|
US8871754B2
(en)
|
2012-11-19 |
2014-10-28 |
Irm Llc |
Compounds and compositions for the treatment of parasitic diseases
|
EP2925757B1
(en)
|
2012-11-19 |
2017-10-04 |
Novartis AG |
Compounds and compositions for the treatment of parasitic diseases
|
CN104797585B
(zh)
|
2012-11-19 |
2017-08-15 |
拜耳医药股份公司 |
氨基咪唑并哒嗪
|
JP6437452B2
(ja)
|
2013-01-14 |
2018-12-12 |
インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation |
Pimキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
|
ME03780B
(me)
|
2013-01-15 |
2021-04-20 |
Incyte Holdings Corp |
Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
|
EP2951181A1
(en)
|
2013-01-30 |
2015-12-09 |
Bayer Pharma Aktiengesellschaft |
Amidoimidazopyridazines as mknk-1 kinase inhibitors
|
US20160287589A1
(en)
|
2013-02-20 |
2016-10-06 |
Bayer Pharma Aktiengesellschaft |
Substituted-imidazopyridazines
|
EA030705B1
(ru)
|
2013-03-06 |
2018-09-28 |
Инсайт Холдингс Корпорейшн |
Способы и промежуточные соединения при получении ингибитора jak
|
EP2964230A4
(en)
*
|
2013-03-07 |
2016-10-26 |
Califia Bio Inc |
KINASEHEMMER WITH MIXED ABSTRACT AND TREATMENT PROCESS THEREWITH
|
CA2906262A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Oncodesign S.A. |
Macrocyclic salt-inducible kinase inhibitors
|
JP6023630B2
(ja)
*
|
2013-04-03 |
2016-11-09 |
株式会社ヤクルト本社 |
チアゾロン誘導体
|
CN105492011A
(zh)
|
2013-04-08 |
2016-04-13 |
丹尼斯·M·布朗 |
不理想给药化学化合物的治疗增效
|
JP6851826B2
(ja)
*
|
2013-07-19 |
2021-03-31 |
オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. |
がんの治療のためのpimキナーゼ阻害剤と組み合わせたペプチドエポキシケトンプロテアソーム阻害剤
|
ES2792549T3
(es)
|
2013-08-07 |
2020-11-11 |
Incyte Corp |
Formas de dosificación de liberación sostenida para un inhibidor de JAK1
|
WO2015027124A1
(en)
|
2013-08-23 |
2015-02-26 |
Incyte Corporation |
Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
|
AR097543A1
(es)
*
|
2013-09-06 |
2016-03-23 |
Lexicon Pharmaceuticals Inc |
COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
|
CN105899512A
(zh)
|
2014-01-09 |
2016-08-24 |
拜耳医药股份公司 |
可用于治疗过度增殖性和/或血管生成疾病的酰胺基团取代的咪唑并哒嗪
|
CN103864800A
(zh)
*
|
2014-04-03 |
2014-06-18 |
定陶县友帮化工有限公司 |
6-氯咪唑并[1,2-b]哒嗪的合成方法
|
WO2015184305A1
(en)
|
2014-05-30 |
2015-12-03 |
Incyte Corporation |
TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
|
GB201410817D0
(en)
*
|
2014-06-17 |
2014-07-30 |
Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R & D |
Therapeutic agents
|
US9822124B2
(en)
|
2014-07-14 |
2017-11-21 |
Incyte Corporation |
Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
|
US9580418B2
(en)
|
2014-07-14 |
2017-02-28 |
Incyte Corporation |
Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
|
BR112017004035B1
(pt)
*
|
2014-09-17 |
2023-11-14 |
Oncodesign Precision Medicine (OPM) |
Inibidores macrocíclicos de rip2 quinase e composições farmacêuticas
|
CN113354649A
(zh)
|
2014-11-16 |
2021-09-07 |
阵列生物制药公司 |
一种新的晶型
|
US9540347B2
(en)
|
2015-05-29 |
2017-01-10 |
Incyte Corporation |
Pyridineamine compounds useful as Pim kinase inhibitors
|
AR105967A1
(es)
|
2015-09-09 |
2017-11-29 |
Incyte Corp |
Sales de un inhibidor de pim quinasa
|
TW201718546A
(zh)
|
2015-10-02 |
2017-06-01 |
英塞特公司 |
適用作pim激酶抑制劑之雜環化合物
|
CA3003153A1
(en)
|
2015-10-26 |
2017-05-04 |
Loxo Oncology, Inc. |
Point mutations in trk inhibitor-resistant cancer and methods relating to the same
|
EP3432886B1
(en)
|
2016-03-25 |
2021-06-02 |
University of Maryland, Baltimore County |
Pim kinase inhibitors in combination with rna splicing modulators/inhibitors for treatment of cancers
|
PE20181888A1
(es)
|
2016-04-04 |
2018-12-11 |
Loxo Oncology Inc |
Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
|
US10045991B2
(en)
|
2016-04-04 |
2018-08-14 |
Loxo Oncology, Inc. |
Methods of treating pediatric cancers
|
KR20210010652A
(ko)
|
2016-04-04 |
2021-01-27 |
록쏘 온콜로지, 인코포레이티드 |
소아암을 치료하는 방법
|
RU2745953C2
(ru)
|
2016-05-18 |
2021-04-05 |
Локсо Онколоджи, Инк. |
Способ получения (s)-n-(5-((r)-2-(2,5-дифторфенил)пирролидин-1-ил)-пиразоло[1,5-a]пиримидин-3-ил)-3-гидроксипирролидин-1-карбоксамида и его солей
|
JOP20190092A1
(ar)
|
2016-10-26 |
2019-04-25 |
Array Biopharma Inc |
عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
|
JOP20190213A1
(ar)
|
2017-03-16 |
2019-09-16 |
Array Biopharma Inc |
مركبات حلقية ضخمة كمثبطات لكيناز ros1
|
KR20190141722A
(ko)
*
|
2017-04-21 |
2019-12-24 |
킨 테라퓨틱스 |
인돌 ahr 억제제 및 이의 용도
|
CN111542522B
(zh)
*
|
2017-08-11 |
2021-10-15 |
苏州韬略生物科技有限公司 |
可用作激酶抑制剂的被取代的吡唑并嘧啶
|
CN111163766A
(zh)
|
2017-08-17 |
2020-05-15 |
医肯纳肿瘤学公司 |
Ahr抑制剂和其用途
|
CN112739345A
(zh)
|
2017-11-06 |
2021-04-30 |
斯奈普生物公司 |
Pim激酶抑制剂组合物,方法和其用途
|
US10596161B2
(en)
|
2017-12-08 |
2020-03-24 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
PL3746429T3
(pl)
|
2018-01-30 |
2022-06-20 |
Incyte Corporation |
Procesy do otrzymywania (1-(3-fluoro-2-(trifluorometylo)izonikotynoilo)piperydyn-4-onu)
|
WO2019191684A1
(en)
|
2018-03-30 |
2019-10-03 |
Incyte Corporation |
Treatment of hidradenitis suppurativa using jak inhibitors
|
US20210113562A1
(en)
|
2018-04-13 |
2021-04-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer
|
EP3924351A4
(en)
|
2019-02-12 |
2022-12-21 |
Sumitomo Pharma Oncology, Inc. |
FORMULATIONS COMPRISING HETEROCYCLIC PROTEIN KINASE INHIBITORS
|
KR20220107213A
(ko)
|
2019-11-22 |
2022-08-02 |
인사이트 코포레이션 |
Alk2 억제제 및 jak2 억제제를 포함하는 병용 요법
|
US11591339B2
(en)
|
2019-11-26 |
2023-02-28 |
Ikena Oncology, Inc. |
Solid forms of (R)-N-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[ 1,5-a][1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine maleate as aryl hydrocarbon receptor (AHR) inhibitors
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
JP2023541262A
(ja)
*
|
2020-09-14 |
2023-09-29 |
ザ ユニバーシティー オブ サセックス |
Lemurチロシンキナーゼ3の小分子阻害剤
|
WO2022140769A1
(en)
*
|
2020-12-22 |
2022-06-30 |
Enliven Therapeutics, Inc. |
Lactam (hetero)arylfusedpyrimidine derivatives as inhibitors of erbb2
|
US20240124469A1
(en)
*
|
2021-02-08 |
2024-04-18 |
Hangzhou Biosun Pharmaceutical Co., Ltd. |
Pim kinase inhibitor
|
WO2023057394A1
(en)
*
|
2021-10-04 |
2023-04-13 |
Forx Therapeutics Ag |
N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
|